Communiqués Senzime AB

Actions

SEZI

SE0002478776

Equipement, fournitures et distribution médicale

Marché Fermé - Nasdaq Stockholm Autres places de cotation 18:00:00 31/07/2026			Varia. 5j.	Varia. 1 janv.
3,700 ^SEK	-.--%		+2,78%	-31,48%

16/07	Senzime AB (publ) publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
16/07	Transcript : Senzime AB, Q2 2026 Earnings Call, Jul 16, 2026

Communiqués

16/07	Interim report Q2 2026: Strong sensor sales and improved margins, despite continued U.S. monitor market headwinds	AQ
15/07	Senzime and Philips Medical Systems enter development and commercialization partnership	AQ
13/07	Senzime : Invitation to presentations of Senzime's second quarter 2026 report	PU
13/07	Invitation to presentations of Senzime’s second quarter 2026 report	AQ
29/06	Senzime : TetraGraph system receives ANVISA regulatory approval in Brazil	PU
29/06	Senzime’s TetraGraph system receives ANVISA regulatory approval in Brazil	AQ
05/06	Senzime to Showcase Expanded TetraGraph Capabilities with Launch of TetraAnalytics at Euroanaesthesia 2026	AQ
03/06	Senzime strengthens position in pediatric anesthesia by securing another hospital contract and highlighting positive outcome data	AQ
01/06	Senzime Advances Sustainable Anesthesia Monitoring with Launch of New EMG Sensor	AQ
27/05	From science to practice: Senzime obtains FDA 510(k) clearance for enhanced TetraGraph system	AQ
19/05	BULLETIN FROM ANNUAL GENERAL MEETING IN SENZIME AB (PUBL)	AQ
29/04	Senzime strengthens U.S. operations with new leadership appointments	AQ
24/04	Senzime : Compensation report (Compensation report 2025)	PU
24/04	Senzime's TetraGraph System Contracted on Three Leading GPO Agreements in the US	AQ
24/04	Senzime’s TetraGraph System Contracted on Three Leading GPO Agreements in the US	AQ
24/04	Senzime publishes annual and sustainability report for 2025	AQ
23/04	Senzime (Q1 Review): Temporary growth dip, with Q2 recovery expected	AQ
22/04	Margins Strengthened and Cash Flow Improved Despite a Temporary Dip in The Growth Trajectory. Full-Year Targets Remain on Track	AQ
22/04	Senzime : Interim Q1 ENG (20260422 781cfeb5 2f83 4805 86ac f84314ab5d25 1)	PU
22/04	Margins strengthened and cash flow improved despite a temporary dip in the growth trajectory. Full-year targets remain on track.	AQ
20/04	Senzime wins expanded contract within leading southeastern US hospital system	AQ
17/04	Notice of Annual General Meeting in Senzime AB (publ)	AQ
17/04	Invitation to Presentations of Senzime's First Quarter 2026 Report	AQ
17/04	Invitation to presentations of Senzime’s first quarter 2026 report	AQ
09/04	Senzime secures strategic hospital orders within leading US integrated healthcare delivery network	AQ